NCT06042647CompletedPhase 4
Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis
A Demonstration of the Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion as Compared to 0.05% Clobetasol Propionate Cream in the Treatment of Psoriasis
Source: ClinicalTrials.gov · Last updated 18 Nov 2023
Brief summary (registry, in English)
The objective of this research is to demonstrate superior anti-inflammatory effects, as demonstrated by a reduction in TNF-a and IL-17A, with tazarotene/halobetasol lotion in patients with mild to moderate plaque type psoriasis as compared to clobetasol propionate 0.05% cream.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 6 Sept 2023
- Start date
- 13 Jul 2023
- Primary completion date
- 13 Nov 2023
- Lead sponsor
- Dermatology Consulting Services, PLLC
- Diseases
- Psoriasis
- NCT number
- NCT06042647
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 10
- From 13 Jul 2023 to the primary completion date, 13 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects who are currently participating in any other clinical study (i.e., dermal patch, use tests, investigational drug or devices, etc.).
- Subjects using any type of lotion, medication, or other topical product to the psoriasis plaques.
Other illness
- Subjects with known allergies or sensitivities to ingredients contained in the test products.
- Subjects with an allergy to latex or adhesives.
Other
- Subjects with pustular or erythrodermic psoriasis.
- Subjects who are pregnant or nursing or planning to become pregnant during the course of the study.
- Subjects viewed by the investigator as not being able to complete the study.
Who the study is looking for
- Males or non-pregnant females 18+ years of age.
- Plaque type mild to moderate psoriasis suitable for topical treatment.
- The presence of 2 plaques suitable for tape stripping
- Subjects must be willing to allow a series of tape pieces to be pressed and removed from 2 target psoriasis plaques.
- Subjects must be in general good health as determined from a medical history.
- Subjects must read and sign the informed consent form after the nature of the study has been fully explained.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dermatology Consulting Services, PLLC Coordinator of this site? Confirm its status | High Point | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.